They discovered that ribociclib reduced Rb expression and induced G1 cell cycle arrest in SR-HepG2 cells with Rb-high/p16-low protein expression profiles, indicating that ribociclib may be a good choice for the treatment of certain sorafenib-resistant HCC. The gene discussed is RB1; the disease is hepatocellular carcinoma.